Baird raised the firm’s price target on Stryker (SYK) to $405 from $378 and keeps an Outperform rating on the shares. The firm said 3Q was another solid quarter with global organic growth reaccelerating to the double-digits, orthopedic pricing turning positive for first time in a decade, and EPS growing at/above mid-teens.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter